NEW YORK (GenomeWeb News) – Med BioGene on Friday reported that its net loss rose 22 percent for the third quarter as it prepares for the US launch of its LungExpress Dx test in mid-2009.
 
The Vancouver, British Columbia-based firm posted a net loss of C$675,383 (US$547,694), or C$.02 per share, compared to a net loss of C$552,563, or C$.02 per share, for the third quarter of 2007.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.